Chief Scientific Officer
Dr Mitrophanous joined Oxford BioMedica in 1997. He has over 20 years of lentiviral vector experience covering a range of technical disciplines, including the development of gene and cell therapies, delivery platform technologies, bioprocessing and analytics. He is a recognised world-class expert in the field, a named inventor on numerous lentiviral vector patents and an author of a number of key papers, which have been published in The Lancet and Human Gene Therapy. In his current role, he is responsible for the development of Oxford BioMedica’s new product candidates and LentiVector® platform. He holds a PhD in Molecular Biology from University College London and has conducted post-doctoral research at the University of Oxford. He is a member of the UK BioIndustry Association Cell and Gene Therapy Advisory Committee.